目的 探究腎康栓聯(lián)合腎衰寧片治療慢性腎功能衰竭的臨床療效。方法 收集2013年3月—2015年2月到重慶市永川區(qū)中醫(yī)院腎病科就診的慢性腎功能衰竭患者64例,隨機分為對照組和治療組,每組各32例。對照組在常規(guī)治療前提下口服腎衰寧片,5片/次,3次/d。治療組在對照組治療基礎上直腸給予腎康栓,5粒/d,早、中、晚各1粒,剩余2粒于患者入睡前使用。兩組均連續(xù)治療45 d。觀察兩組的臨床療效,同時比較兩組治療前后血尿素氮(BUN)、血肌酐(Scr)、內(nèi)生肌酐清除率(Ccr)、24 h尿蛋白(24 h Upm)的變化情況。結果 治療后,對照組和治療組的總有效率分別為62.5%、75.0%,兩組比較差異有統(tǒng)計學意義(P<0.05)。治療后,兩組患者BUN、Scr、24 h Upm均較治療前顯著降低,Ccr顯著升高,同組治療前后差異具有統(tǒng)計學意義(P<0.05);且治療組這些觀察指標改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學意義(P<0.05)。對照組和治療組不良反應發(fā)生率分別為9.36%、6.25%,兩組比較差異無統(tǒng)計學意義。結論 腎康栓聯(lián)合腎衰寧片治療慢性腎功能衰竭的臨床療效較好,可改善腎功能相關指標,且不良反應發(fā)生率較低,具有一定的臨床推廣應用價值。

Objective To explore the clinical effect of Shenkang Suppository combined with Shenshuaining Tablets in treatment of chronic renal failure. Methods Patients (64 cases) with chronic renal failure in Traditional Chinese Medicine Hospital of Yongchuan District in Chongqing from March 2013 to February 2015 were randomly divided into control and treatment groups, and each group had 32 cases. The patients in the control group were po administered with Shenshuaining Tablets on the basis of routine therapy, 5 tablets/time, three times daily. The patients in the treatment group were given Shenkang Suppository by rectum on the basis of control group, 5 grains/d, early, middle and late each 1 grain, and the remaining 2 grains were used before sleeping. The patients in two groups were treated for 45 d. After treatment, the clinical efficacy were evaluated, and the changes of BUN, Scr, Ccr, and 24 h Upm before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 62.5% and 75.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, BUN, Scr and 24 h Upm in two groups were significantly decreased, Ccr was significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). The adverse reactions incidences in control and treatment groups were 9.36% and 6.25%, and there was no statistical significance between the two groups. Conclusion Shenkang Suppository combined with Shenshuaining Tablets has clinical curative effect in treatment of chronic renal failure, and can improve indicators related renal function with a lower incidence of adverse reactions, which has a certain clinical application value.